Cargando…
A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
For decades, no clear consensus existed on the standard treatment option for malignant tumors of the external auditory canal, an extremely rare disease. Here we report the case of a 55-year-old female patient with secretory carcinoma that originated from the left external auditory canal. Magnetic re...
Autores principales: | Ando, Yuichi, Morita, Sachi, Shimokata, Tomoya, Tsuzuki, Toyonori, Inafuku, Shigeru, Iwami, Kenichiro, Brega, Nicoletta, Akagawa, Takashi, Tsujino, Toshiaki, Ogawa, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522948/ https://www.ncbi.nlm.nih.gov/pubmed/36186229 http://dx.doi.org/10.1007/s13691-022-00559-6 |
Ejemplares similares
-
Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018) -
Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020) -
Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022) -
Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020) -
Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)